Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up – Should You Buy?

Nuvectis Pharma, Inc. (NASDAQ:NVCT – Get Free Report) shares gapped up prior to trading on Thursday. The stock had previously closed at $19.20, but opened at $20.48. Nuvectis Pharma shares last traded at $20.2750, with a volume of 7,363 shares traded.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Lucid Cap Mkts upgraded shares of Nuvectis Pharma to a “strong-buy” rating in a research report on Tuesday, September 1st. Weiss Ratings raised shares of Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 21st. HC Wainwright restated a “buy” rating and issued a $39.00 price objective on shares of Nuvectis Pharma in a report on Thursday, September 24th. Wall Street Zen lowered shares of Nuvectis Pharma from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. Finally, Zacks Research cut shares of Nuvectis Pharma from a “hold” rating to a “strong sell” rating in a research note on Thursday, November 5th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, Nuvectis Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $36.25.

Get Our Latest Report on NVCT

Nuvectis Pharma Price Performance

The stock has a 50 day moving average price of $20.36 and a 200-day moving average price of $15.35. The stock has a market capitalization of $685.72 million, a P/E ratio of -10.55 and a beta of -0.21.

Nuvectis Pharma (NASDAQ:NVCT – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.78). Research analysts predict that Nuvectis Pharma, Inc. will post -1.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nuvectis Pharma

A number of large investors have recently bought and sold shares of the stock. Soleus Capital Management L.P. lifted its position in Nuvectis Pharma by 71.1% in the third quarter. Soleus Capital Management L.P. now owns 1,710,658 shares of the company’s stock valued at $36,129,000 after purchasing an additional 710,658 shares during the last quarter. BlackRock Inc. bought a new position in shares of Nuvectis Pharma in the second quarter worth approximately $18,414,000. Iridian Asset Management LLC CT grew its holdings in shares of Nuvectis Pharma by 2.1% in the third quarter. Iridian Asset Management LLC CT now owns 793,207 shares of the company’s stock worth $16,753,000 after purchasing an additional 16,129 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Nuvectis Pharma in the second quarter worth approximately $5,057,000. Finally, Oppenheimer & Co. Inc. increased its stake in shares of Nuvectis Pharma by 17.3% in the third quarter. Oppenheimer & Co. Inc. now owns 86,291 shares of the company’s stock worth $1,822,000 after buying an additional 12,725 shares during the period. 96.77% of the stock is owned by hedge funds and other institutional investors.

Nuvectis Pharma Company Profile

(Get Free Report)

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with serious diseases, particularly cancer. Its research and development programs target molecular pathways that may be relevant to specific tumor types. The company’s pipeline includes NXP800, an investigational small-molecule drug designed to inhibit the heat shock factor 1 pathway, and NXP900, an investigational inhibitor of the SRC and YES1 kinases. Nuvectis has studied NXP800 in ovarian cancer and is developing NXP900 for solid tumors; both remain investigational and are not approved medicines.

Featured Stories

Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.